Macter introduces Hepanox anticoagulant in PFS format

Macter International Limited has launched Hepanox, containing enoxaparin sodium, in a pre-filled syringe format, according to Mettis Global. The product belongs to the LMWH group of anticoagulants, which the company is adding to its biopharmaceuticals portfolio. The company informed the Exchange through a notification, and the report is dated September 25, 2026.

According to the report, the launch is meant to bolster Macter's standing in anticoagulant treatment and marks a milestone in widening its biopharmaceutical range. The report ties the move to long-term growth and to a focus on changing healthcare needs. It does not provide any sales, pricing or earnings figures for Hepanox.

The filing is a product launch notice, so it contains no reported revenue or profit impact. For shareholders, it is a portfolio update rather than a financial disclosure.